Clarine Halvorsen, 319-356-3944
Participants in this research study have metastatic renal cell carcinoma and have recently had surgery to remove the areas of cancer recurrence. The purpose of this study is to determine whether taking an oral drug known as pazopanib (Votrient®) will reduce the risk of the cancer recurring in the future. Pazopanib is approved by the U.S. Food and Drug Administration (FDA) for subjects who have metastatic renal cell carcinoma. However, it has not been tested in subjects who have had all visible areas of their cancer removed surgically, and is considered experimental (not approved by the FDA) in this situation. Investigators don't know if pazopanib will be helpful to subjects in this scenario. There is currently no standard of care for subjects in this situation but careful observation without treatment is considered reasonable. Approximately 14 people will take part in this study conducted by investigators at the University of Iowa. About 180 people may take part in this study nationwide.
Please help us improve your experience on our website by completing a brief survey
Yes, I'll give feedback No, Thanks
Your browser does not support iframes.